Ideal Design for Premature Ejaculation ( PE ) Drug Trials

In volume 23 of the Indian Journal of Urology published in 2007, CG McMahon discusses the ideal design of premature ejaculation ( PE ) drug trials. With the many difficulties in defining and measuring premature ejaculation ( PE ), consistent trial design is important when trying to compare results. Premature ejaculation ( PE ) can be divided into two groups: lifelong and acquired. It is important to differentiate between those two groups during pharmacological testing. In addition, screening out co-morbid disorders such as erectile dysfunction is also critical. Patients with erectile dysfunction should either be excluded from the drug testing or at least categorized separately so as not to skew results.

cMahon also feels that patients with other urological disorders or concerns be excluded from the study, as well as patients with a history of drug or alcohol abuse. McMahon further recommends that intravaginal ejaculatory latency time (IELT) should be measured with a stopwatch or a Sexual Assessment Monitor (SAM) to provide an accurate measurement of whether or not the drug is effective from the treatment group to the control group. Finally, patients should be queried as to perceived ejaculatory control, sexual satisfaction, and distress in order to test for all subcomponents of premature ejaculation ( PE ). Including all these factors will yield results that can be replicated more easily from one clinical trial to another.

Post this article on:
	del.icio.us		Digg.com		Netscape.com
	Yahoo.com		Google.com		StumbleUpon